ABSTRACT:
Background: Chronic kidney disease (CKD) is a risk factor for end-stage renal failure and cardiovascular events. High incidence of anaemia is found in CKD stage 3 and 4. MIRCERA a continuous erythropoietin receptor activator is in development to provide anaemia correction and stable maintenance of haemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease (CKD). This study examined its efficacy when administered up to once monthly in patients with CKD. Methodology: This study involved a prospective examination of haemoglobin levels in CKD patients by collecting and documentation the information of the patient including patient demographics, past medical history, medication history, and laboratory data. All enrolled patients were assessed for haemoglobin levels for every 4 weeks. Results: The haemoglobin levels after 24 weeks treatment with Mircera were found to be significantly high when compared with baseline haemoglobin levels in CKD patients who didn’t receive Mircera (P<0.0001). Conclusion: Mircera demonstrated improved efficacy in treating anemia in patients with CKD when given twice weekly for 24 weeks.